Frontlight ResearchEarly access
Taking peoplePhase 3
Comparison of STep-up and step-down therapeutic strategies in childhood ARthritiS
Key facts
- Who runs it
- Giannina Gaslini Institute For Scientific Hospitalization And Care
- Where
- Italy20 sites in 1 countryChoose a country to see its sites
- Status
- Recruiting
- Phase
- Phase 3
- People taking part
- 260 people, planned
- Started
- 4 Sept 2024
- Planned end
- 31 May 2026
- Type of study
- Interventional
- Record updated
- 30 September 2025
Who can take part
- Age
- Up to 17 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 14 criteriaShow less
Who can take part
- Newly-diagnosed and synthetic or biologic DMARD-naïve children (only treatment with 1 NSAID is allowed and no corticosteroid joint injections prior to randomization) with a JIA classified according to the following ILAR categories: i. Oligoarthritis, ii. Rheumatoid factor negative polyarthritis
- Active arthritis
- Onset of JIA symptoms no more than 6 months before randomization, IV. Age 2 to 16 years at enrolment
- Female of child-bearing potential must have a negative pregnancy test at the beginning of the trial. If sexually active, they must agree to use highly effective contraceptive measures, throughout study participation, and must have no intention of conceiving during the course of the study. Post-pubertal males must have no plans to father a child during the study and agree to use highly effective contraceptive measures if sexually active
- Ability to comply with the entire study procedures, ability to communicate meaningfully with the investigational staff, competence to give written informed consent; to be applied to the parents and/or patients, as appropriate
- Duly executed, written, informed consent/assent obtained from the parents/patient
- Age 2 to 16 years at enrolment
Who cannot take part
- Tuberculosis related issues: patients are excluded from the study if they have: a. Active TB or a history of incompletely treated TB; b. PPD or QuantiFERON-TB positive patients (with no active disease) unless it is documented by a specialist that the patient has been adequately treated for TB and can start treatment with a biologic agent, based on the medical judgment of the study investigator and / or an infectious disease specialist; c. Suspected extrapulmonary TB infection; d. Patients at high risk of contracting TB, such as close contact with individual with active or latent TB
- Previous treatment with any synthetic or biologic DMARD
- Any live attenuated vaccine within 4 weeks prior to the baseline visit, such as varicella-zoster, oral polio, measles, mumps or rubella vaccines and throughout the study. Killed or inactive vaccine may be permitted based on the investigator’s judgment
- Prior or current history of malignancy or any other significant concomitant illness(es) as per the treating physician evaluation
- Any of the following laboratory abnormalities based on the most recent laboratory results: a. White blood cell (WBC) count <3.50 x 103/mm3 (SI units: <3.50 x 109/L) and neutrophils < 1x109/L; b. Hemoglobin < 8.5 g/dL (SI units: <85 g/L); c. Platelet Count < 125,0000/mm3 or ≥1,000,000/mm3 (SI units: <125 x 109/L or ≥1,000 x 109/L; d. Aspartate aminotransaminase (AST) or alanine aminotransaminase (ALT) ≥ 2.0 x upper limit of normal (ULN)
- Classification in one of the following JIA categories: systemic arthritis, RF-positive polyarthritis, psoriatic arthritis, enthesitis-related arthritis, undifferentiated arthritis
- Patients who need systemic treatment for uveitis
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
to compare the effectiveness of a conventional therapeutic regimen, based on treatment escalation (Step-up strategy) and driven by the treat-to-target approach, with that of an early aggressive intervention based on a combination of conventional and biological DMARDs (Step-down strategy).
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).How to verify a trial in the registry
- Publications
- Methotrexate for juvenile idiopathic arthritis.The Cochrane database of systematic reviews, 2024
- Looking for the best strategy to treat children with new onset juvenile idiopathic arthritis: presentation of the "comparison of STep-up and step-down therapeutic strategies in childhood ARthritiS" (STARS) trial.Pediatric rheumatology online journal, 2022
- Record updated
- 30 September 2025